CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Coverage and limitations
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 ASIA-PACIFIC IVF MARKET ANALYSIS
3.1 Market definition and scope
3.2 Overview
3.3 Drivers
3.3.1 Delay in family planning reduces chances of conception
3.3.2 Decline in birth rate
3.3.3 Emotional problems
3.4 Restraints
3.5 Asia-Pacific embryo transfer market, by Country
3.6 Asia-Pacific embryo transfer market by Cycle Types
3.7 Asia-Pacific embryo transfer market by End Users
3.8 Company Profile
3.8.1 Thermo Fisher Scientific, Inc.
3.8.2 Merck KGaA
CHAPTER 4 INDIA EMBRYO TRANSFER MARKET
4.1 Overview
4.2 India Embryo Transfer Market by End Users
4.2.1 Fertility clinics
4.2.2 Hospitals
4.2.3 Surgical centers
4.2.4 Clinical research institutes
4.3 India IVF Market by Cycle Type
4.3.1 Fresh IVF cycles (non-donor)
4.3.2 Thawed IVF cycles (non-donor)
4.3.3 Donor egg IVF cycles
4.4 Drivers
4.5 Restraints
4.6 Regulatory issues, legislations, and authorities
4.7 Insurance reimbursement scenario
4.8 Company/Hospitals/Clinics Profile
4.8.1 Sun Pharmaceutical Industries Ltd.
4.8.2 Trivector Origio Scientific Pvt. Ltd
4.8.3 Lab IVF Asia Pte. Ltd.
4.8.4 LG Life Sciences.
4.8.5 Cadila Healthcare Ltd. (Zydus Cadila group)
4.8.6 Bourn Hall Clinic
4.8.7 Morpheus IVF Fertility Center
4.8.8 Southend Fertility and IVF Centre
4.8.9 Nova IVI Fertility
4.8.10 Bloom Fertility Center
4.8.11 Manipal Ankur
4.8.12 Cloudnine
CHAPTER 5 CHINA EMBRYO TRANSFER MARKET
5.1 Overview
5.2 China Embryo Transfer Market by End Users
5.2.1 Fertility clinics
5.2.2 Hospitals
5.2.3 Surgical centers
5.2.4 Clinical research institutes
5.3 China IVF Market by Cycle Type
5.3.1 Fresh IVF cycles (non-donor)
5.3.2 Thawed IVF cycles (non-donor)
5.3.3 Donor egg IVF cycles
5.4 Drivers
5.4.1 Increased rate of infertility
5.4.2 Change in lifestyle
5.5 Restraints
5.5.1 Cost of living
5.6 Regulatory issues, legislations, and authorities
5.7 Insurance reimbursement scenario
5.8 Company/Hospitals/Clinics Profile
5.8.1 Cook Medical, Inc.
5.8.2 Vitrolife AB
5.8.3 Centre for Reproductive Medicine
5.8.4 Reproductive & Genetic Hospital Citic-Xiangya
5.8.5 Shenyang International Hospital
5.8.6 Shandong Provincial Hospital
CHAPTER 6 JAPAN EMBRYO TRANSFER MARKET
6.1 Overview
6.2 Japan Embryo Transfer Market by End Users
6.2.1 Fertility clinics
6.2.2 Hospitals
6.2.3 Surgical centers
6.2.4 Clinical research institutes
6.3 Japan IVF Market by Cycle Type
6.3.1 Fresh IVF cycles (non-donor)
6.3.2 Thawed IVF cycles (non-donor)
6.4 Drivers
6.5 Restraints
6.6 Regulatory issues, legislations, and authorities
6.7 Insurance reimbursement scenario
6.8 Company/Hospitals/Clinics Profile
6.8.1 Merck KGaA
6.8.2 IVF Namba Clinic
6.8.3 Iwaki Womens Clinic
6.8.4 Sanno Hospital
CHAPTER 7 AUSTRALIA EMBRYO TRANSFER MARKET
7.1 Overview
7.2 Australia Embryo Transfer Market by End Users
7.2.1 Fertility clinics
7.2.2 Hospitals
7.2.3 Surgical centers
7.2.4 Clinical research institutes
7.3 Australia IVF Market by Cycle Type
7.3.1 Fresh IVF cycles (non-donor)
7.3.2 Thawed IVF cycles (non-donor)
7.4 Drivers
7.5 Restraints
7.5.1 Emotional and physical stress
7.5.2 No guarantee
7.5.3 Surplus embryos
7.6 Regulatory issues, legislations, and authorities
7.6.1 Common Law
7.6.2 Legislative responses to IVF
7.6.3 Non-legislative regulation for the practice of IVF
7.7 Insurance reimbursement scenario
7.8 Company/Hospitals/Clinics Profile
7.8.1 Genea Biomedx
7.8.2 Thermo Fisher Scientific, Inc.
7.8.3 Virtus Health
7.8.4 Monash IVF
7.8.5 City Fertility
7.8.6 Flinders Fertility
CHAPTER 8 NEW ZEALAND EMBRYO TRANSFER MARKET
8.1 Overview
8.2 New Zealand Embryo Transfer Market by End Users
8.2.1 Fertility clinics
8.2.2 Hospitals
8.2.3 Surgical centers
8.2.4 Clinical research institutes
8.3 New Zealand IVF Market by Cycle Type
8.3.1 Fresh IVF cycles (non-donor)
8.3.2 Thawed IVF cycles (non-donor)
8.3.3 Donor egg IVF cycles
8.4 Drivers
8.5 Restraints
8.6 Regulatory issues, legislations, and authorities
8.7 Insurance reimbursement scenario
8.8 Hospitals/Clinics Profile
8.8.1 Fertility Associates
8.8.2 Fertility Plus
8.8.3 Reporomed
CHAPTER 9 KOREA EMBRYO TRANSFER MARKET
9.1 Overview
9.2 Korea Embryo Transfer Market by End Users
9.2.1 Fertility clinics
9.2.2 Hospitals
9.2.3 Surgical centers
9.2.4 Clinical research institutes
9.3 Korea IVF Market by Cycle Type
9.3.1 Fresh IVF cycles (non-donor)
9.3.2 Thawed IVF cycles (non-donor)
9.3.3 Donor egg IVF cycles
9.4 Drivers
9.5 Restraints
9.6 Regulatory issues, legislations, and authorities
9.7 Insurance reimbursement scenario
9.8 Hospitals/Clinics Profile
9.8.1 Cha General Hospital
9.8.2 Maria Fertility Hospital
CHAPTER 10 THAILAND EMBRYO TRANSFER MARKET
10.1 Overview
10.2 Thailand Embryo Transfer Market by End Users
10.2.1 Fertility clinics
10.2.2 Hospitals
10.2.3 Surgical centers
10.2.4 Clinical research institutes
10.3 Thailand IVF Market by Cycle Type
10.3.1 Fresh IVF cycles (non-donor)
10.3.2 Thawed IVF cycles (non-donor)
10.3.3 Donor egg IVF cycles
10.4 Drivers
10.4.1 Government initiatives
10.4.2 Surrogacy is economical as compared to developed countries
10.4.3 Boost in medical tourism
10.5 Restraints
10.5.1 Comparatively low success rate
10.5.2 Ethical issues in allowing gender selection
10.6 Regulatory issues, legislations, and authorities
10.7 Insurance reimbursement scenario
10.8 Hospitals/Clinics Profile
10.8.1 Bangkok Fertility Center
10.8.2 Siriraj Hospital
10.8.3 Ramathibodi Hospital
10.8.4 Perfect Woman Institute Piyavate Hospital
10.8.5 Jetanin Institute for Assisted Reproduction
CHAPTER 11 SINGAPORE EMBRYO TRANSFER MARKET
11.1 Overview
11.2 Singapore Embryo Transfer Market by End Users
11.2.1 Fertility clinics
11.2.2 Hospitals
11.2.3 Surgical centers
11.2.4 Clinical research institutes
11.3 Singapore IVF Market by Cycle Type
11.3.1 Fresh IVF cycles (non-donor)
11.3.2 Thawed IVF cycles (non-donor)
11.4 Drivers
11.4.1 Government funding and tax rebates for parents
11.4.2 Rising infertility rate
11.4.3 Increase in success rate
11.5 Restraints
11.5.1 High cost of IVF treatment and lower success rate
11.6 Regulatory issues, legislations, and authorities
11.7 Insurance reimbursement scenario
11.8 Company/Clinics Profile
11.8.1 Irvine Scientific
11.8.2 ESCO Technologies Inc.
11.8.3 Leica Microsystems GMBH
11.8.4 NUH IVF Centre
11.8.5 Mount Elizabeth Fertility Center
11.8.6 Thomson Fertility Centre
11.8.7 Raffles Fertility Centre
CHAPTER 12 MALAYSIAN EMBRYO TRANSFER MARKET
12.1 Overview
12.2 Malaysia Embryo Transfer Market by End Users
12.2.1 Fertility clinics
12.2.2 Hospitals
12.2.3 Surgical centers
12.2.4 Clinical research institutes
12.3 Malaysia IVF Market by Cycle Type
12.3.1 Fresh IVF cycles (non-donor)
12.3.2 Thawed IVF cycles (non-donor)
12.3.3 Donor egg IVF cycles
12.4 Drivers
12.4.1 Increase in government initiatives
12.4.2 Increase in the number of foreign patients
12.4.3 Decrease in rate of fertility and growing acceptability of IVF
12.5 Restraints
12.6 Regulatory issues, legislations, and authorities
12.7 Insurance reimbursement scenario
12.8 Clinics Profile
12.8.1 Subang Fertility Center
12.8.2 Concept Fertility Centre
12.8.3 TMC Fertility Center
CHAPTER 13 INDONESIAN EMBRYO TRANSFER MARKET
13.1 Overview
13.2 Indonesia Embryo Transfer Market by End Users
13.2.1 Fertility clinics
13.2.2 Hospitals
13.2.3 Surgical centers
13.2.4 Clinical research institutes
13.3 Indonesia IVF Market by Cycle Type
13.3.1 Fresh IVF cycles (non-donor)
13.3.2 Thawed IVF cycles (non-donor)
13.3.3 Donor egg IVF cycles
13.4 Drivers
13.4.1 Increase in disposable income
13.4.2 Advances in embryo transfer technology
13.4.3 Decline in fertility rate
13.5 Restraints
13.5.1 Physical and emotional impact due to low success rate
13.6 Regulatory issues, legislations, and authorities
13.7 Insurance reimbursement scenario
13.8 Clinics Profile
13.8.1 Morula IVF
13.8.2 Yasmin IVF
13.8.3 Aster Fertility Clinic
13.8.4 Fertility Centre, Siloam Hospitals Surabana
CHAPTER 14 PHILIPPINES EMBRYO TRANSFER MARKET
14.1 Overview
14.2 Philippines Embryo Transfer Market by End Users
14.2.1 Fertility clinics
14.2.2 Hospitals
14.2.3 Surgical centers
14.2.4 Clinical research institutes
14.3 Philippines IVF market by cycle type
14.3.1 Fresh IVF cycles (non-donor)
14.3.2 Thawed IVF cycles (non-donor)
14.3.3 Donor egg IVF cycles
14.4 Drivers
14.4.1 Improve the replacement population
14.4.2 Advancement in technology
14.5 Restraints
14.6 Regulatory issues, legislations, and authorities
14.7 Insurance reimbursement scenario
14.8 Clinic Profile
14.8.1 Victory Art Lab
14.8.2 CRM-MIA-Philippines
CHAPTER 15 VIETNAM EMBRYO TRANSFER MARKET
15.1 Overview
15.2 Vietnam Embryo Transfer Market by End Users
15.2.1 Fertility clinics
15.2.2 Hospitals
15.2.3 Surgical centers
15.2.4 Clinical research institutes
15.3 Vietnam IVF market by cycle type
15.3.1 Fresh IVF cycles (non-donor)
15.3.2 Thawed IVF cycles (non-donor)
15.3.3 Donor egg IVF cycles
15.4 Drivers
15.4.1 Decline in fertility rate
15.4.2 Reasonable cost and good success rate
15.5 Restraints
15.6 Regulatory issues, legislations, and authorities
15.7 Insurance reimbursement scenario
15.8 Hospital/Clinic Profile
15.8.1 IVF Lab Tu Du Hospital Vietnam
15.8.2 IVF Van Hanh
15.8.3 Sinh Hospital
15.8.4 Tu Du - Ho Chi Minh City Vietnam
CHAPTER 16 REST OF ASIA-PACIFIC EMBRYO TRANSFER MARKET
16.1 Overview
16.2 Rest of Asia-Pacific Embryo Transfer Market by End Users
16.2.1 Fertility clinics
16.2.2 Hospitals
16.2.3 Surgical centers
16.2.4 Clinical research institutes
16.3 Rest of Asia-Pacific IVF Market by Cycle Type
16.3.1 Fresh IVF cycles (non-donor)
16.3.2 Thawed IVF cycles (non-donor)
16.3.3 Donor egg IVF cycles
16.4 Drivers
16.4.1 Increase in disposable income
16.4.2 Advances in IVF technology
16.4.3 Decline in fertility rate
16.5 Restraints
16.5.1 Physical and emotional impact due to low success rate
16.6 Regulatory Issues, legislations, and Authorities
16.7 Insurance Reimbursement Scenario
16.8 Hospitals/Clinics Profile
16.8.1 Fertility Centre, Siloam Hospitals Surabana
16.8.2 CRM-MIA-Philippines
16.8.3 IVFAS